Bill Amendment: IL SB2952 | 2017-2018 | 100th General Assembly
NOTE: For additional amemendments please see the Bill Drafting List
Bill Title: CONTROL SUB-PMP&ADV COMMITTEE
Status: 2018-08-26 - Public Act . . . . . . . . . 100-1093 [SB2952 Detail]
Download: Illinois-2017-SB2952-Senate_Amendment_001.html
Bill Title: CONTROL SUB-PMP&ADV COMMITTEE
Status: 2018-08-26 - Public Act . . . . . . . . . 100-1093 [SB2952 Detail]
Download: Illinois-2017-SB2952-Senate_Amendment_001.html
| |||||||
| |||||||
| |||||||
1 | AMENDMENT TO SENATE BILL 2952
| ||||||
2 | AMENDMENT NO. ______. Amend Senate Bill 2952 by replacing | ||||||
3 | everything after the enacting clause with the following:
| ||||||
4 | "Section 5. The Illinois Controlled Substances Act is | ||||||
5 | amended by changing Sections 316 and 320 as follows:
| ||||||
6 | (720 ILCS 570/316)
| ||||||
7 | Sec. 316. Prescription Monitoring Program. | ||||||
8 | (a) The Department must provide for a
Prescription | ||||||
9 | Monitoring Program for Schedule II, III, IV, and V controlled | ||||||
10 | substances that includes the following components and | ||||||
11 | requirements:
| ||||||
12 | (1) The
dispenser must transmit to the
central | ||||||
13 | repository, in a form and manner specified by the | ||||||
14 | Department, the following information:
| ||||||
15 | (A) The recipient's name and address.
| ||||||
16 | (B) The recipient's date of birth and gender.
|
| |||||||
| |||||||
1 | (C) The national drug code number of the controlled
| ||||||
2 | substance
dispensed.
| ||||||
3 | (D) The date the controlled substance is | ||||||
4 | dispensed.
| ||||||
5 | (E) The quantity of the controlled substance | ||||||
6 | dispensed and days supply.
| ||||||
7 | (F) The dispenser's United States Drug Enforcement | ||||||
8 | Administration
registration number.
| ||||||
9 | (G) The prescriber's United States Drug | ||||||
10 | Enforcement Administration
registration number.
| ||||||
11 | (H) The dates the controlled substance | ||||||
12 | prescription is filled. | ||||||
13 | (I) The payment type used to purchase the | ||||||
14 | controlled substance (i.e. Medicaid, cash, third party | ||||||
15 | insurance). | ||||||
16 | (J) The patient location code (i.e. home, nursing | ||||||
17 | home, outpatient, etc.) for the controlled substances | ||||||
18 | other than those filled at a retail pharmacy. | ||||||
19 | (K) Any additional information that may be | ||||||
20 | required by the department by administrative rule, | ||||||
21 | including but not limited to information required for | ||||||
22 | compliance with the criteria for electronic reporting | ||||||
23 | of the American Society for Automation and Pharmacy or | ||||||
24 | its successor. | ||||||
25 | (2) The information required to be transmitted under | ||||||
26 | this Section must be
transmitted not later than the end of |
| |||||||
| |||||||
1 | the next business day after the date on which a
controlled | ||||||
2 | substance is dispensed, or at such other time as may be | ||||||
3 | required by the Department by administrative rule.
| ||||||
4 | (3) A dispenser must transmit the information required | ||||||
5 | under this Section
by:
| ||||||
6 | (A) an electronic device compatible with the | ||||||
7 | receiving device of the
central repository;
| ||||||
8 | (B) a computer diskette;
| ||||||
9 | (C) a magnetic tape; or
| ||||||
10 | (D) a pharmacy universal claim form or Pharmacy | ||||||
11 | Inventory Control form;
| ||||||
12 | (4) The Department may impose a civil fine of up to | ||||||
13 | $100 per day for willful failure to report controlled | ||||||
14 | substance dispensing to the Prescription Monitoring | ||||||
15 | Program. The fine shall be calculated on no more than the | ||||||
16 | number of days from the time the report was required to be | ||||||
17 | made until the time the problem was resolved, and shall be | ||||||
18 | payable to the Prescription Monitoring Program.
| ||||||
19 | (b) The Department, by rule, may include in the | ||||||
20 | Prescription Monitoring Program certain other select drugs | ||||||
21 | that are not included in Schedule II, III, IV, or V. The | ||||||
22 | Prescription Monitoring Program does not apply to
controlled | ||||||
23 | substance prescriptions as exempted under Section
313.
| ||||||
24 | (c) The collection of data on select drugs and scheduled | ||||||
25 | substances by the Prescription Monitoring Program may be used | ||||||
26 | as a tool for addressing oversight requirements of long-term |
| |||||||
| |||||||
1 | care institutions as set forth by Public Act 96-1372. Long-term | ||||||
2 | care pharmacies shall transmit patient medication profiles to | ||||||
3 | the Prescription Monitoring Program monthly or more frequently | ||||||
4 | as established by administrative rule. | ||||||
5 | (d) The Department of Human Services shall appoint a | ||||||
6 | full-time Clinical Director of the Prescription Monitoring | ||||||
7 | Program. | ||||||
8 | (e) (Blank). | ||||||
9 | (f) Within one year of the effective date of this | ||||||
10 | amendatory Act of the 100th General Assembly, the Department | ||||||
11 | shall adopt rules requiring all Electronic Health Records | ||||||
12 | Systems to interface with the Prescription Monitoring Program | ||||||
13 | application program on or before January 1, 2021 to ensure that | ||||||
14 | all providers have access to specific patient records during | ||||||
15 | the treatment of their patients. These rules shall also address | ||||||
16 | the electronic integration of pharmacy records with the | ||||||
17 | Prescription Monitoring Program to allow for faster | ||||||
18 | transmission of the information required under this Section. | ||||||
19 | The Department shall establish actions to be taken if a | ||||||
20 | prescriber's Electronic Health Records System does not | ||||||
21 | effectively interface with the Prescription Monitoring Program | ||||||
22 | within the required timeline. | ||||||
23 | (g) The Department, in consultation with the Advisory | ||||||
24 | Committee, shall adopt rules allowing licensed prescribers or | ||||||
25 | pharmacists who have registered to access the Prescription | ||||||
26 | Monitoring Program to authorize a licensed or non-licensed |
| |||||||
| |||||||
1 | designee employed in that licensed prescriber's office or a | ||||||
2 | licensed designee in a licensed pharmacist's pharmacy, and who | ||||||
3 | has received training in the federal Health Insurance | ||||||
4 | Portability and Accountability Act to consult the Prescription | ||||||
5 | Monitoring Program on their behalf. The rules shall include | ||||||
6 | reasonable parameters concerning a practitioner's authority to | ||||||
7 | authorize a designee, and the eligibility of a person to be | ||||||
8 | selected as a designee. | ||||||
9 | (Source: P.A. 99-480, eff. 9-9-15; 100-564, eff. 1-1-18.)
| ||||||
10 | (720 ILCS 570/320)
| ||||||
11 | Sec. 320. Advisory committee.
| ||||||
12 | (a) There is created a Prescription Monitoring Program | ||||||
13 | Advisory Committee to
assist the Department of Human Services | ||||||
14 | in implementing the Prescription Monitoring Program created by | ||||||
15 | this Article and to advise the Department on the professional | ||||||
16 | performance of prescribers and dispensers and other matters | ||||||
17 | germane to the advisory committee's field of competence.
| ||||||
18 | (b) The Clinical Director of the Prescription Monitoring | ||||||
19 | Program shall appoint members to
serve on the advisory | ||||||
20 | committee. The advisory committee shall be composed of | ||||||
21 | prescribers and dispensers as follows: 4 physicians licensed to | ||||||
22 | practice medicine in all its branches; one advanced practice | ||||||
23 | registered nurse; one physician assistant; one optometrist; | ||||||
24 | one dentist; one podiatric physician; and 3 pharmacists. The | ||||||
25 | Clinical Director of the Prescription Monitoring Program may |
| |||||||
| |||||||
1 | appoint a representative of an organization representing a | ||||||
2 | profession required to be appointed. The Clinical Director of | ||||||
3 | the Prescription Monitoring Program shall serve as the chair of | ||||||
4 | the committee.
| ||||||
5 | (c) The advisory committee may appoint its other officers | ||||||
6 | as it deems
appropriate.
| ||||||
7 | (d) The members of the advisory committee shall receive no | ||||||
8 | compensation for
their services as members of the advisory | ||||||
9 | committee but may be reimbursed for
their actual expenses | ||||||
10 | incurred in serving on the advisory committee.
| ||||||
11 | (e) The advisory committee shall: | ||||||
12 | (1) provide a uniform approach to reviewing this Act in | ||||||
13 | order to determine whether changes should be recommended to | ||||||
14 | the General Assembly; | ||||||
15 | (2) review current drug schedules in order to manage | ||||||
16 | changes to the administrative rules pertaining to the | ||||||
17 | utilization of this Act; | ||||||
18 | (3) review the following: current clinical guidelines | ||||||
19 | developed by health care professional organizations on the | ||||||
20 | prescribing of opioids or other controlled substances; | ||||||
21 | accredited continuing education programs related to | ||||||
22 | prescribing and dispensing; programs or information | ||||||
23 | developed by health care professional organizations that | ||||||
24 | may be used to assess patients or help ensure compliance | ||||||
25 | with prescriptions; updates from the Food and Drug | ||||||
26 | Administration, the Centers for Disease Control and |
| |||||||
| |||||||
1 | Prevention, and other public and private organizations | ||||||
2 | which are relevant to prescribing and dispensing; relevant | ||||||
3 | medical studies; and other publications which involve the | ||||||
4 | prescription of controlled substances; | ||||||
5 | (4) make recommendations for inclusion of these | ||||||
6 | materials or other studies which may be effective resources | ||||||
7 | for prescribers and dispensers on the Internet website of | ||||||
8 | the inquiry system established under Section 318; | ||||||
9 | (5) on at least a quarterly basis, review the content | ||||||
10 | of the Internet website of the inquiry system established | ||||||
11 | pursuant to Section 318 to ensure this Internet website has | ||||||
12 | the most current available information; | ||||||
13 | (6) on at least a quarterly basis, review opportunities | ||||||
14 | for federal grants and other forms of funding to support | ||||||
15 | projects which will increase the number of pilot programs | ||||||
16 | which integrate the inquiry system with electronic health | ||||||
17 | records; and | ||||||
18 | (7) on at least a quarterly basis, review communication | ||||||
19 | to be sent to all registered users of the inquiry system | ||||||
20 | established pursuant to Section 318, including | ||||||
21 | recommendations for relevant accredited continuing | ||||||
22 | education and information regarding prescribing and | ||||||
23 | dispensing. | ||||||
24 | (f) The Clinical Director of the Prescription Monitoring | ||||||
25 | Program shall select 6 5 members, 3 physicians , and 2 | ||||||
26 | pharmacists, and one dentist, of the Prescription Monitoring |
| |||||||
| |||||||
1 | Program Advisory Committee to serve as members of the peer | ||||||
2 | review subcommittee. The purpose of the peer review | ||||||
3 | subcommittee is to advise the Program on matters germane to the | ||||||
4 | advisory committee's field of competence, establish a formal | ||||||
5 | peer review of professional performance of prescribers and | ||||||
6 | dispensers, and develop communications to transmit to | ||||||
7 | prescribers and dispensers. The deliberations, information, | ||||||
8 | and communications of the peer review subcommittee are | ||||||
9 | privileged and confidential and shall not be disclosed in any | ||||||
10 | manner except in accordance with current law. | ||||||
11 | (1) The peer review subcommittee shall periodically | ||||||
12 | review the data contained within the prescription | ||||||
13 | monitoring program to identify those prescribers or | ||||||
14 | dispensers who may be prescribing or dispensing outside the | ||||||
15 | currently accepted standards in the course of their | ||||||
16 | professional practice. | ||||||
17 | (2) The peer review subcommittee may identify | ||||||
18 | prescribers or dispensers who may be prescribing outside | ||||||
19 | the currently accepted medical standards in the course of | ||||||
20 | their professional practice and send the identified | ||||||
21 | prescriber or dispenser a request for information | ||||||
22 | regarding their prescribing or dispensing practices. This | ||||||
23 | request for information shall be sent via certified mail, | ||||||
24 | return receipt requested. A prescriber or dispenser shall | ||||||
25 | have 30 days to respond to the request for information. | ||||||
26 | (3) The peer review subcommittee shall refer a |
| |||||||
| |||||||
1 | prescriber or a dispenser to the Department of Financial | ||||||
2 | and Professional Regulation in the following situations: | ||||||
3 | (i) if a prescriber or dispenser does not respond | ||||||
4 | to three successive requests for information; | ||||||
5 | (ii) in the opinion of a majority of members of the | ||||||
6 | peer review subcommittee, the prescriber or dispenser | ||||||
7 | does not have a satisfactory explanation for the | ||||||
8 | practices identified by the peer review subcommittee | ||||||
9 | in its request for information; or | ||||||
10 | (iii) following communications with the peer | ||||||
11 | review subcommittee, the prescriber or dispenser does | ||||||
12 | not sufficiently rectify the practices identified in | ||||||
13 | the request for information in the opinion of a | ||||||
14 | majority of the members of the peer review | ||||||
15 | subcommittee. | ||||||
16 | (4) The Department of Financial and Professional | ||||||
17 | Regulation may initiate an investigation and discipline in | ||||||
18 | accordance with current laws and rules for any prescriber | ||||||
19 | or dispenser referred by the peer review subcommittee. | ||||||
20 | (5) The peer review subcommittee shall prepare an | ||||||
21 | annual report starting on July 1, 2017. This report shall | ||||||
22 | contain the following information: the number of times the | ||||||
23 | peer review subcommittee was convened; the number of | ||||||
24 | prescribers or dispensers who were reviewed by the peer | ||||||
25 | review committee; the number of requests for information | ||||||
26 | sent out by the peer review subcommittee; and the number of |
| |||||||
| |||||||
1 | prescribers or dispensers referred to the Department of | ||||||
2 | Financial and Professional Regulation. The annual report | ||||||
3 | shall be delivered electronically to the Department and to | ||||||
4 | the General Assembly. The report prepared by the peer | ||||||
5 | review subcommittee shall not identify any prescriber, | ||||||
6 | dispenser, or patient. | ||||||
7 | (Source: P.A. 99-480, eff. 9-9-15; 100-513, eff. 1-1-18 .)
| ||||||
8 | Section 99. Effective date. This Act takes effect upon | ||||||
9 | becoming law.".
|